Anti-Tumour Necrosis Factor therapy for Dupuytren’s disease: a randomised dose response proof of concept phase 2a clinical trial
<p>Background: Dupuytren’s disease is a common fibrotic condition of the hand that causes irreversible flexion contractures of the fingers, with no approved therapy for early stage disease. Our previous analysis of surgically-excised tissue defined tumour necrosis factor (TNF) as a potential t...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Elsevier
2018
|